Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.33. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VWO | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | — |
52-Week High | $30.81 | $61.24 |
52-Week Low | $16.87 | $51.20 |
Enterprise Value | $1.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
VWO trades at $60.47, up 0.85% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers low-cost exposure to emerging markets with a 0.06% expense ratio and a 2.4% dividend yield, attracting institutional inflows as seen in recent SEC filings. Recent news highlights strong investor interest in emerging markets ex-China and AI-driven growth in regions like Taiwan and Thailand.
Outlook is positive due to record capital flows into emerging markets and diversification benefits, but risks include China's economic volatility and currency fluctuations. The ETF's low fees and focus on high-growth economies support long-term potential, though short-term technical indicators suggest caution near resistance at $61.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
